Aspire Biopharma signs agreement to buy Dura Driver Control Systems for $30 million cash

Aspire Biopharma Holdings, Inc.

ASBP

0.00

Aspire Biopharma signed a definitive share purchase agreement to buy Dura Driver Control Systems for USD 30 million cash.
Target posted FY2025 unaudited revenue above USD 200 million, net income above USD 17 million, adjusted EBITDA above USD 22 million.
Deal expected to close in Q3 2026, subject to customary closing conditions.
Dura Driver Control Systems will become a wholly owned subsidiary; CEO Hans Vorstenbosch is set to remain in charge.
Buyer indicated it does not anticipate raising new equity to complete the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606120830ACCESSWRNAPR_____1175992) on June 12, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.